Cipher Pharmaceuticals

191 articles with Cipher Pharmaceuticals

• Cipher Pharmaceuticals Reports First Quarter 2019 Financial Results

  5/10/2019

  Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three months ended March 31st, 2019.

• Notice of Cipher Pharmaceuticals Q1 2019 Conference Call

  5/1/2019

  Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2019 financial results conference call on Friday, May 10, 2019. The call will be hosted by Robert Tessarolo, President and Chief Executive Officer, and Nadine Jutlah, Interim Chief Financial Officer.

• Cipher Pharmaceuticals Appoints Mr. Craig Mull to the Board of Directors

  3/26/2019

  Cipher Pharmaceuticals Inc. today announced that Mr. Craig Mull was appointed as a member of the Company's Board of Directors, effective immediately.

• Cipher Pharmaceuticals Announces Change to Management Team

  3/20/2019

  Cipher Pharmaceuticals Inc. announced that Stephen Lemieux, Chief Financial Officer and Secretary of Cipher has resigned to pursue other career opportunities.

• Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

  3/19/2019

  Cipher Pharmaceuticals Inc. announced its financial and operating results for the three and twelve months ended December 31st, 2018.

• Notice of Cipher Pharmaceuticals Q4 2018 Conference Call

  3/15/2019

  Cipher Pharmaceuticals Inc. announced the details of its Q4 2018 financial results conference call on Tuesday, March 19, 2019.

• Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada

  12/18/2018

  Cipher Pharmaceuticals Inc. announced that its New Drug Submission ("NDS") for A-101 40% topical solution ("A-101 40%") for the treatment of raised seborrheic keratoses ("SKs") has been accepted for review by Health Canada.

• Cipher Pharmaceuticals Announces PLECANATIDE Accepted for Review by Health Canada

  12/17/2018

  Cipher Pharmaceuticals (TSX:CPH) today  announced that its New Drug Submission ("NDS") for plecanatide for irritable bowel syndrome with constipation ("IBS-C") has been accepted by Health Canada. Cipher acquired the Canadian rights to develop, market, distribute and sell plecanatide (branded as TRULANCE® in the U.S.) from Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) ("Synergy") in February 2018.

• Cipher Pharmaceuticals to Host Investor Webcast on December 11TH, 2018

  12/5/2018

   Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that it will host a webcast investor presentation on Tuesday, December 11th at 11:00 AM ET.

• Cipher Pharmaceuticals adds new Vice President, Canadian Commercial Operations

  12/4/2018

  Cipher Pharmaceuticals Inc. today announced that pharmaceutical industry commercial executive, Michael Milloy, has joined the Company in the position of Vice President, Canadian Commercial Operations.

• Cipher Pharmaceuticals Reports Q3 2018 Results

  11/7/2018

  Canadian product revenue increased 27%

• 

  Synergy Pharma Struggles Despite Promising Market Opportunities in 2019

  10/26/2018

  After providing an update of its ongoing strategic review, New York-based Synergy Pharmaceuticals’ stock plunged more than 71 percent.

• Notice of Cipher Pharmaceuticals Q3 2018 Conference Call

  10/24/2018

  Cipher Pharmaceuticals Inc. today announced the details of its Q3 2018 financial results conference call on Wednesday, November 7, 2018.

• Cipher Pharmaceuticals Announces Canadian Launch of Brinavess (vernakalant hydrochloride)

  10/24/2018

  Brinavess® (vernakalant hydrochloride) is for the rapid conversion of recent onset atrial fibrillation

• Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to MOB-015 from Moberg Pharma for the topical treatment of Onychomycosis

  9/18/2018

  Transaction broadens Cipher's Canadian portfolio providing entry into rapidly growing market

• Cipher Pharmaceuticals Reports Q2 2018 Results

  8/10/2018

  Canadian product revenue increased 33%

• Cipher Pharmaceuticals Announces Amended Distribution and Supply Agreement for Absorica

  7/30/2018

  New portfolio royalty extends through December 2024

• Notice of Cipher Pharmaceuticals Q2 2018 Conference Call

  7/23/2018

  Cipher Pharmaceuticals Inc. announced the details of its Q2 2018 financial results conference call on Friday, August 10, 2018.

• Cipher Pharmaceuticals Adds New Vice President, Scientific & Medical Affairs

  6/6/2018

  Dr. Gajewczyk has more than 25 years of pharmaceutical industry experience in the research, clinical development and commercialization of pharmaceutical, biologics, vaccine and medical device products.

• Cipher Pharmaceuticals Inc. Completes Acquisition of 100% of Cardiome Pharma Corp.

  5/16/2018

  Effective May 15, 2018, the previously announced acquisition by Cipher Pharmaceuticals Inc. ("Cipher") of the Canadian business portfolio of Cardiome Pharma Corp. was completed.